Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster
NEW YORK and MAINZ, GERMANY, August 31, 2022— Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Covid Vaccine | COVID-19 | Emergency Medicine | Food and Drug Administration (FDA) | Germany Health | Pfizer | Pharmaceuticals | Vaccines